German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for patients with high and very high risk of relapse. Patients with standard risk receive further consolidation and reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. A MRD based risk stratification and treatment decision is developed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johann Wolfgang Goethe University Hospital
• Treatments: 6-Mercaptopurine; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Fludarabine; Idarubicin; Ifosfamide; Mercaptopurine; Methotrexate; Prednisolone; Thioguanine; Vincristine; Vindesine

Criteria

Inclusion Criteria:

• Acute lymphoblastic leukemia (pro-B, common, pre-B, early T, T)

• Age 15-65 yrs (*55-65 years if biologically younger according to general condition)

Exclusion Criteria:

• Severe comorbidity

• Cytostatic pre-treatment

• Pregnancy

• Missing written informed consent